BIOGEN
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Biogen Pharmachem do?
Sun Techno Overseas Ltd is a company engaged in share trading, stock broking, consulting, commodities trading in agro-based and precious metals, and diversifying into the power sector with wind power generation plant.
Who are the competitors of Biogen Pharmachem?
Biogen Pharmachem major competitors are Integ.Pro, Amrapali Industries, Rotographics (India), Cerebra Integ. Tech, MRC Agrotech, Rama Vision, Filtra Consultants. Market Cap of Biogen Pharmachem is ₹80 Crs. While the median market cap of its peers are ₹82 Crs.
Is Biogen Pharmachem financially stable compared to its competitors?
Biogen Pharmachem seems to be less financially stable compared to its competitors. Altman Z score of Biogen Pharmachem is 0 and is ranked 8 out of its 8 competitors.
Does Biogen Pharmachem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Biogen Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Biogen Pharmachem allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Biogen Pharmachem balance sheet?
Biogen Pharmachem balance sheet is weak and might have solvency issues
Is the profitablity of Biogen Pharmachem improving?
The profit is oscillating. The profit of Biogen Pharmachem is ₹1.21 Crs for TTM, ₹1.93 Crs for Mar 2024 and ₹0.46 Crs for Mar 2023.
Is the debt of Biogen Pharmachem increasing or decreasing?
The net debt of Biogen Pharmachem is decreasing. Latest net debt of Biogen Pharmachem is -₹2.02 Crs as of Mar-25. This is less than Mar-24 when it was -₹0.03 Crs.
Is Biogen Pharmachem stock expensive?
Biogen Pharmachem is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Biogen Pharmachem is 66.23, while 3 year average PE is 57.14. Also latest EV/EBITDA of Biogen Pharmachem is 47.69 while 3yr average is 210.
Has the share price of Biogen Pharmachem grown faster than its competition?
Biogen Pharmachem has given lower returns compared to its competitors. Biogen Pharmachem has grown at ~24.68% over the last 7yrs while peers have grown at a median rate of 29.26%
Is the promoter bullish about Biogen Pharmachem?
There is Insufficient data to gauge this.
Are mutual funds buying/selling Biogen Pharmachem?
There is Insufficient data to gauge this.